Detailed Narrative
Robust Financial Performance in FY26 and Q4
Glenmark Pharmaceuticals Limited delivered a strong financial performance, with consolidated revenue for Q4 FY26 reaching INR 37,706 million, marking a 15.8% year-on-year growth compared to INR 32,562 million in the prior year. For the full fiscal year 2026, the company's consolidated revenue surged by 27.5% to INR 169,825 million, up from INR 133,217 million in FY25, reflecting broad-based growth across its key markets.
Landmark IGI Licensing Deal and Pipeline Advancement
A significant highlight of FY26 was IGI's landmark licensing deal with AbbVie for ISB 2001, which included a USD 700 million upfront payment and a total potential deal value of USD 1.925 billion, along with tiered double-digit royalties. This transaction validates IGI's proprietary BEAT platform. The company is also advancing its broader IGI pipeline, having selected a clinical candidate for ISB-2301 with IND submission intended by the end of calendar year 2026.
Strategic Expansion in Oncology and Global Brands
Glenmark accelerated its oncology business expansion in India and Emerging Markets through in-licensing commercial rights for Trastuzumab Rezetecan from Hengrui Pharma and Aumolertinib from Hansoh Pharma. The global brand RYALTRIS continued its strong momentum, recording over $100 million in sales last year with approximately 50% plus secondary sales growth across its commercial markets. RYALTRIS is now commercialized in 55 markets and is expected to launch in 8-10 additional markets, including Brazil, in the coming quarters⏳.
U.S. Market Revival and Respiratory Franchise Growth
The U.S. business, which had been a drag for the past four years, is poised for significant growth in FY27. This is driven by the first ANDA approval for Fluticasone MDI (generic to FloVent 44mcg) with CGT designation and 180-day exclusivity, and the planned launch of 2-3 additional respiratory products in FY27. The Monroe facility also received VAI classification from the U.S. FDA in November 2025, enabling a restart of commercial manufacturing and supporting future growth in injectables.
India Business Outperformance and New Product Launches
The India formulation business delivered a strong performance, growing 13.5% for the full year and 12.3% in Q4, significantly outpacing the IPM growth of 9% and 10.1% respectively. This growth was fueled by new launches such as TEVIMBRA, BRUKINSA, NEBZMART GFB nebulizer (world's first triple neb for COPD), and GLIPIQ (semaglutide vials/injection for diabetes). The GLIPIQ launch is expected to revitalize the previously lagging diabetes segment, with growth anticipated from Q1 FY27 onwards.
Robust Balance Sheet and Disciplined Capital Allocation
Glenmark achieved a gross debt-free status by the end of FY26, maintaining a healthy cash position of INR 1,200 crores. The company plans disciplined capital allocation, with R&D spend maintained at 8% of sales and total capex normalizing to around INR 900 crores from FY27 onwards. This strategy focuses on strategic investments in core businesses, innovative pipeline, and maintaining working capital efficiencies to address geopolitical and supply chain uncertainties.
Optimistic FY27 Outlook with Clear Targets
Management provided an optimistic outlook for FY27, targeting consolidated revenue between INR 17,000 crores and INR 18,000 crores, and an EBITDA margin of 21% to 22%. This growth is expected to be driven by new product launches, strategic investments and expansion in India and Emerging Markets, and the anticipated turnaround and strong performance of the U.S. business, which will see full traction from new respiratory launches.